Direkt zum Inhalt
Merck
  • BRF1 mutations alter RNA polymerase III-dependent transcription and cause neurodevelopmental anomalies.

BRF1 mutations alter RNA polymerase III-dependent transcription and cause neurodevelopmental anomalies.

Genome research (2015-01-07)
Guntram Borck, Friederike Hög, Maria Lisa Dentici, Perciliz L Tan, Nadine Sowada, Ana Medeira, Lucie Gueneau, Holger Thiele, Maria Kousi, Francesca Lepri, Larissa Wenzeck, Ian Blumenthal, Antonio Radicioni, Tito Livio Schwarzenberg, Barbara Mandriani, Rita Fischetto, Deborah J Morris-Rosendahl, Janine Altmüller, Alexandre Reymond, Peter Nürnberg, Giuseppe Merla, Bruno Dallapiccola, Nicholas Katsanis, Patrick Cramer, Christian Kubisch
ZUSAMMENFASSUNG

RNA polymerase III (Pol III) synthesizes tRNAs and other small noncoding RNAs to regulate protein synthesis. Dysregulation of Pol III transcription has been linked to cancer, and germline mutations in genes encoding Pol III subunits or tRNA processing factors cause neurogenetic disorders in humans, such as hypomyelinating leukodystrophies and pontocerebellar hypoplasia. Here we describe an autosomal recessive disorder characterized by cerebellar hypoplasia and intellectual disability, as well as facial dysmorphic features, short stature, microcephaly, and dental anomalies. Whole-exome sequencing revealed biallelic missense alterations of BRF1 in three families. In support of the pathogenic potential of the discovered alleles, suppression or CRISPR-mediated deletion of brf1 in zebrafish embryos recapitulated key neurodevelopmental phenotypes; in vivo complementation showed all four candidate mutations to be pathogenic in an apparent isoform-specific context. BRF1 associates with BDP1 and TBP to form the transcription factor IIIB (TFIIIB), which recruits Pol III to target genes. We show that disease-causing mutations reduce Brf1 occupancy at tRNA target genes in Saccharomyces cerevisiae and impair cell growth. Moreover, BRF1 mutations reduce Pol III-related transcription activity in vitro. Taken together, our data show that BRF1 mutations that reduce protein activity cause neurodevelopmental anomalies, suggesting that BRF1-mediated Pol III transcription is required for normal cerebellar and cognitive development.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Glycerin, for molecular biology, ≥99.0%
Sigma-Aldrich
Glycerin, ACS reagent, ≥99.5%
Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
Glycerin, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
Glycerin, ≥99.5%
Sigma-Aldrich
HEPES, BioUltra, for molecular biology, ≥99.5% (T)
Sigma-Aldrich
Ethylendiamintetraessigsäure, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
Anti-acetyliertes-Tubulin-Antikörper, monoklonaler Antikörper der Maus in Maus hergestellte Antikörper, clone 6-11B-1, purified from hybridoma cell culture
Sigma-Aldrich
Ethylendiamintetraessigsäure -Lösung, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Glycerin, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Glycerin -Lösung, 83.5-89.5% (T)
Sigma-Aldrich
HEPES-Pufferlösung, 1 M in H2O
Sigma-Aldrich
Glycerin, BioUltra, for molecular biology, anhydrous, ≥99.5% (GC)
SAFC
HEPES
USP
Glycerin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Glycerin, FCC, FG
Sigma-Aldrich
Ethylendiamintetraessigsäure, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
Ethylendiamintetraessigsäure, 99.995% trace metals basis
Supelco
Glycerin, Pharmaceutical Secondary Standard; Certified Reference Material